Developing a new oral treatment for pulmonary arterial hypertension.
Development of a novel disease modifying oral therapy for pulmonary arterial hypertension.
This study is testing a new oral medication called VN-1032 that aims to help people with pulmonary arterial hypertension (PAH) by slowing down the disease and easing symptoms.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vasculonics, LLC NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11006726 on NIH RePORTER |
What this research studies
This research focuses on creating a novel oral therapy, VN-1032, aimed at modifying the disease progression of pulmonary arterial hypertension (PAH). PAH is a serious condition characterized by high blood pressure in the lungs, leading to severe health complications. The approach involves targeting specific biological pathways, particularly the Aryl hydrocarbon Receptor (AhR) and asymmetric dimethylarginine (ADMA), which are known to contribute to the disease. By inhibiting these pathways, the therapy aims to not only alleviate symptoms but also slow down or halt the progression of PAH.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension who are currently experiencing disease progression despite existing therapies.
Not a fit: Patients who do not have pulmonary arterial hypertension or those whose condition is stable and well-managed with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that modifies the course of pulmonary arterial hypertension, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While there has been significant research into PAH treatments, the specific approach targeting AhR and ADMA with VN-1032 represents a novel strategy that has not been extensively tested in clinical settings.
Where this research is happening
Indianapolis, United States
- Vasculonics, LLC — Indianapolis, United States (Active)
Researchers
- Principal investigator: Singh, Jaipal — Vasculonics, LLC
- Study coordinator: Singh, Jaipal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.